Partnering Inflammation/Autoimmune Drugs Offers Sizzle And Steak
Executive Summary
As Big Pharma companies back away from developing primary care products because of rising development costs and regulatory risk, they are increasingly turning to specialty medicines to fill their pipeline holes. One therapeutic area of particular interest: the inflammation/auto-immune space